Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease by Ellrichmann, Gisa et al.
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128
Models of Huntington’s Disease
Gisa Ellrichmann
1, Elisabeth Petrasch-Parwez
2, De-Hyung Lee
1, Christiane Reick
1, Larissa Arning
3,
Carsten Saft
1, Ralf Gold
1, Ralf A. Linker
1*
¤
1Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, 2Department of Neuroanatomy and Molecular Brain Research, Ruhr-
University Bochum, Bochum, Germany, 3Department of Human Genetics, Ruhr-University Bochum, Bochum, Germany
Abstract
Huntington’s disease (HD) is an autosomal dominantly inherited progressive neurodegenerative disease. The exact sequel of
events finally resulting in neurodegeneration is only partially understood and there is no established protective treatment
so far. Some lines of evidence speak for the contribution of oxidative stress to neuronal tissue damage. The fumaric acid
ester dimethylfumarate (DMF) is a new disease modifying therapy currently in phase III studies for relapsing-remitting
multiple sclerosis. DMF potentially exerts neuroprotective effects via induction of the transcription factor ‘‘nuclear factor E2-
related factor 2’’ (Nrf2) and detoxification pathways. Thus, we investigated here the therapeutic efficacy of DMF in R6/2 and
YAC128 HD transgenic mice which mimic many aspects of HD and are characterized by an enhanced generation of free
radicals in neurons. Treatment with DMF significantly prevented weight loss in R6/2 mice between postnatal days 80–90. At
the same time, DMF treatment led to an attenuated motor impairment as measured by the clasping score. Average survival
in the DMF group was 100.5 days vs. 94.0 days in the placebo group. In the histological analysis on day 80, DMF treatment
resulted in a significant preservation of morphologically intact neurons in the striatum as well as in the motor cortex. DMF
treatment resulted in an increased Nrf2 immunoreactivity in neuronal subpopulations, but not in astrocytes. These
beneficial effects were corroborated in YAC128 mice which, after one year of DMF treatment, also displayed reduced
dyskinesia as well as a preservation of neurons. In conclusion, DMF may exert beneficial effects in mouse models of HD.
Given its excellent side effect profile, further studies with DMF as new therapeutic approach in HD and other
neurodegenerative diseases are warranted.
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Introduction
Huntington’s Disease (HD) is an autosomal dominantly
inherited neurodegenerative disorder caused by a trinucleotide
CAG repeat expansion $36 in the HD gene located on
chromosome 4. The course of HD is characterized by progressive
motor dysfunction, cognitive impairment, affective disorders and
personality changes. The most striking neuropathological feature
of HD is the progressive atrophy of the striatum and cortex
accompanied by neuronal cell loss in these regions [1]. The major
histopathological hallmark is the accumulation of intracellular
huntingtin (Htt) aggregates, which continuously increase as the
disease progresses. The underlying mechanisms of neurodegener-
ation and Htt aggregation are far less well understood. Here, lack
of trophic factors, mitochondrial dysfunction and oxidative stress
may play a role [2]. So far, therapeutic options for HD are limited
to symptomatic treatment approaches and there is no cure for this
devastating disease.
Dimethylfumarate (DMF) is an orally bioavailable fumaric acid
ester (FAE) which is metabolized to methyl hydrogen fumarate [3].
Since 50 years, fumaric acid esters are now in clinical use for the
treatment of psoriasis [4]. In the recent years, DMF was
successfully introduced into the therapy of relapsing-remitting
multiple sclerosis (MS). In a first phase IIb study the modified FAE
BG00012 was successfully tested and phase III studies are
currently ongoing to further explore its therapeutic potential in
this indication. While several dermatologic in vitro studies point at
immunomodulatory effects [5], another primary mode of action of
DMF may be the induction of the nuclear factor E2-related factor
2 (Nrf2) pathway which activates detoxifying phase II enzymes [6].
This pathway may thus play a critical role for cellular protection in
an environment of oxidative stress and may present an interesting
therapeutic target in HD.
Here we explore the potential of DMF in the R6/2 and
YAC128 transgenic murine models of HD. The R6/2 and
YAC128 mouse strains are well characterized animal models
mimicking many histopathological aspects of HD. R6/2 mice
trangenetically express the exon 1 of the human HD gene with
141–157 CAG repeats [7]. In R6/2 mice, motor symptoms like
dyskinesia, ataxia, clasping behaviour, epileptic seizures and
spontaneous shivering movements start at the age of about 6
weeks. Continous weight loss leads to death between 11–14 weeks
of age. From the age of 9–10 weeks, there is a significant neuronal
dysfunction and mice display neuronal atrophy in the striatum [8].
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employed to express a full-length mutant Htt with about 120 CAG
repeats [9,10]. In YAC128 mice, hypoactivity is first seen at the
age of 8 months. Additionally, progressive gait abnormalities,
ataxia, hindlimb clasping and a progressive decline in the forced
motor function as measured by the rotarod test occur over time
[10,11].
In the models of R6/2 and YAC128 mice, we show that DMF
exerts beneficial effects and preserves motor functions as well as
intact neurons which may involve activation of the Nrf2 signalling
pathway.
Materials and Methods
Animal models and treatment procedure
Male R6/2 and YAC128 mice were obtained from the Jackson
Laboratories (Bar Harbor, Maine, USA) and bred at the local
animal care facilities under standardized conditions. Mice were
given food and water at libidum and were weighed daily to obtain
weight curves. In the R6/2 strain, stability of the transgene over at
least 5 generations of backcrossing was proven by PCR (data not
shown). All transgenic mice were heterozygous. All animal
experiments were approved by the local authorities for animal
experimentation (approval ID: 8.87-50.10.32.08.032, 1 8 Protec-
tion of Animals Act). For treatment, mice received either DMF
30 mg/kg body weight in 0.08% methocel as carrier solution or
the same amount of methocel alone as placebo treatment twice
daily via oral gavage. For survival analysis, cohorts of mice were
followed over the course of disease with moribund mice sacrificed
according to animal protection laws.
Behavioral analyses
Over the course of the disease, mice were subjected to
behavioral analyses every second week starting from week 3. An
accelerating rotarod was used to analyse motor coordination and
balance (Ugo Basile, Biological Research Apparatus, Varese,
Italy). Mice were trained twice on the rotarod with 10 rpm for a
maximum of 240 s. During test conditions, the rotarod was
accelerated from 4 to 40 rpm with two trials on the same day.
To analyse limb dyskinesia, the clasping behaviour was assessed
in a blinded manner as described previously [12,13]. Briefly, mice
were vertically suspended for 45 s approximately 40 cm above
ground. Scoring was based on the duration of clasping as follows:
clasping .10 s=score 3, 5–10 s=score 2, 1–5 s=score 1, no
clasping=score 0.
Gait analysis was performed by footprint analysis as described
previously [14]. Analysis included stride-length, hind-base width,
front-base width and overlap indicating the distance from left or
right front footprint to hind footprint.
Cohorts with a maximal number of 47 R6/2 mice per group
(only male mice) and a maximal number of 23 YAC128 mice per
group (only male mice) were tested.
Light- and electronmicroscopical analyses
R6/2 and YAC128 mice were deeply anesthetized with
ketamine, transcardially perfused either with 4% paraformalde-
hyde in phosphate buffered saline (PBS, pH 7.4) for Nissl staining
and immunohistochemistry or 2.5% glutaraldehyde and 4%
paraformaldehyde in PBS (pH 7.4) for semithin and ultrathin
section analyses.
For light microscopy, brains were removed and standardized
2 mm frontal brain slices were prepared using a brain slicer
starting 2 mm rostral of the bregma and embedded in paraffin.
Three mm paraffin sections were subjected to cresyl violet staining
or immunohistochemistry for NeuN (Chemicon MAB377; via
Millipore, Schwalbach, Germany; 1:200) to label neurons,
ubiquitin (Chemicon MAB 1510; 1:1000) or Htt (Chemicon
MAB2166; 1:500) to label Htt aggregates [15,16], and Mac-3 (BD
Pharmingen; Heidelberg, Germany; 1:200) to label activated
microglia/macrophages. Immunohistochemistry for Nrf2 (Santa
Cruz Biotechnology C20 sc-722; Santa Cruz, USA; 1:200) was
analyzed by light microscopy or confocal laser scanning
microscopy in co-localization studies with GFAP (DAKO,
Hamburg, Germany; 1:1000) to label Nrf2 in astrocytes or NeuN
to detect neuronal Nrf2. All histological procedures were
essentially performed as described previously [17].
For electron microscopical analysis, removed brains were
adjusted in a plexiglass frame following the orientation of Paxinos
and Franklin [18], embedded in 2% agarose in PBS and cut into
1.5 mm frontal brain slices with a vibratome cutter. All slices were
photodocumented for later orientation, postfixed with 2% osmium
tetroxide in PBS for 3 hours and embedded in araldite (Serva,
Heidelberg, Germany) as recently described [19]. Blocks with the
striatum and motor cortex were prepared for semithin section
series, cut with a Leica Ultracut UCT microtome and stained with
1% toluidine (pH 9.3). Ultrathin sections (80 mm) were contrasted
with uranyl acetate and lead citrate. Light microscopical pictures
were taken by a CP71 camera (Olympus, Hamburg, Germany).
Ultrathin sections were viewed in a Philips EM 420 electron
microscope documented by the digital system DITABIS (Digital
Biomedical Imaging System, Pforzheim, Germany).
Detection of oxidative chemistry markers in tissue
samples
The presence of reactive oxygen species and other oxidants such
as ONOO
2 was visualized on frozen mouse brain sections from
R6/2 mice and wild-type controls using dihydroethidium as
described previously [20]. After transcardial perfusion with
phosphate buffered saline (PBS, pH 7.4), we applied 5 mM
hydroethidine (Polysciences, CAS Number 104821-25-2) for
30 minutes. Sections were analyzed by confocal laser scanning
microscopy.
Quantification and statistical analyses
All neuropathological and behavioral analyses were performed
completely blinded with respect to treatment allocation. In the
striatum or motor cortex of both hemispheres, quantification of
neuronal densities was performed on standardized sections
comprising an area of 1 mm
2. On 2 sections per animal, 4
standardized areas were analyzed under 40 fold magnification.
Intact neurons were defined by intact shape, regular appearance
and intact processes without formation of vacuoles. Data are
presented as mean 6 SEM. For histological evaluations, statistical
analysis was performed by Mann-Whitney U-test. To assess the
survival of mice, a Kaplan-Meier analysis with Log rank test was
used (all analyses done by Graph Pad Prism 5, San Diego, CA,
USA). A probability level of *p,0.05, **p,0.01, ***p,0.001 was
considered to be statistically significant for all tests.
Results
The symptomatic disease stage in R6/2 mice is associated
with an increased formation of oxygen radicals
In a first step, we examined the formation of free radicals in R6/
2 mice at the age of 3–4 months, i.e. at a time point where mice
are also clinically symptomatic and exhibit severe neurodegener-
ation [21]. Therefore, we stained brain sections with dihydroethi-
dine as a broad-spectrum indicator of oxidative stress. As
Fumaric Acid in Huntington’s Disease
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larger amount of reactive oxygen species in neurons, as detected
by dihydroethidium staining (Fig. 1).
In summary, neurodegeneration in R6/2 mice is associated with
higher levels of oxidative stress in neurons which is well in line with
previous studies [22,23].
The antioxidant DMF treatment leads to a prolonged
survival and preserved body weight in R6/2 mice
Since we found a considerable amount of oxidative stress in the
R6/2 mouse model of HD, we were interested in the clinical
effects of DMF, a compound which has been recently shown to
exert neuroprotective effects via the induction of antioxidant
pathways [6]. After initiation of treatment with DMF at 30 mg/kg
body weight four weeks after birth, R6/2 mice displayed a
maximum weight between days 50 to 70 of age and then lost body
weight concurrent with the progression of motor deficits. Upon
comparison of DMF treated R6/2 mice with controls treated with
carrier solution alone, there was a trend to preserved body weight
after DMF treatment with a significant preservation of body
weight on days 85 and 90 of life (Fig. 2A). Moreover, DMF treated
R6/2 mice displayed a 7% increase in life span. In a Kaplan-
Meier analysis, the median survival after DMF treatment was
100.5 days in contrast to 94.0 days after oral gavage with vehicle
only (Fig. 2B).
In summary, DMF treatment leads to a preserved body weight
and prolonged survival in R6/2 mice.
DMF treatment preserves motor functions in R6/2 mice
In a next step, we correlated the beneficial clinical effects of
DMF in the R6/2 mouse model with behavioral tests of motor
functions. While motor functions generally decreased over time,
analysis of forced motor behaviour in the rotarod test from weeks
10–12 revealed that DMF treatment led to a trend towards
increased time on the rotarod (Fig 3A). Furthermore, R6/2 mice
were tested weekly for clasping behaviour as a marker of
dyskinesia. Up to the age of 9 weeks, there was no difference in
clasping scores between DMF treated mice or methocel treated
controls (Fig. 3C). At 10–12 weeks of age, matched with the
beginning of motor impairment, DMF treatment resulted in a
Figure 1. R6/2 mice display higher levels of oxidative stress. (A, B) Representative confocal laser scanning image from the striatum of a 3
months old R6/2 mouse (male, A) after hydroethidine staining in comparison to the striatum of a 4 months old C57BL/6 mouse (B). (C, D)
Hydroethidine staining of the motor cortex. The same representative R6/2 mouse (C) and C57BL/6 control mouse (D) as in A,B are shown. The amount
of free radicals in neuronal cells is indicated in red. Note the increased immunofluorescence in the R6/2 mouse indicating a higher amount of
oxidative stress in both anatomical regions. Bar=20 mm.
doi:10.1371/journal.pone.0016172.g001
Fumaric Acid in Huntington’s Disease
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16172Figure 2. DMF improves survival and prevents weight loss in R6/2 mice. (A) Comparison of body weight changes in DMF treated male R6/2
mice (black bars) and controls treated with carrier solution alone (white bars). Treatment with DMF prevented weight loss in R6/2 mice on postnatal
days 85 (p=0.05) and 90 (p=0.04). Data are shown as change in body weight (g) on days 80, 85 and 90 to the respective baseline weight at the start
of treatment. Numbers of mice per day of analysis are indicated in the graph. (B) Kaplan Meier survival analysis of male R6/2 mice treated with DMF
(n=14, black curve) or methocel (n=19, grey curve). DMF treatment leads to prolonged survival of R6/2 mice. Confidence interval for mean survival:
DMF 97.7–104.6 vs. methocel 91.22–99.6 days.
doi:10.1371/journal.pone.0016172.g002
Figure 3. DMF preserves motor functions in R6/2 mice. (A) Rotarod analysis. A cohort of R6/2 mice treated with DMF (n=46) or methocel
(n=42) is shown. Although DMF treatment (black bars) leads to a trend towards longer times on the accelerating rod, there is no significant
difference as compared to methocel treated controls (white bars). (B) Representative images of a R6/2 mouse treated with DMF and a mouse treated
with methocel at the age of 12 weeks. Note the clasping of the front- and hindlimbs in the control mouse. (C) Clasping Score. A cohort of R6/2 mice
treated with DMF (n=46, black bars) or methocel (n=42, white bars) is shown. At the age of 12 weeks, there is a significant difference between both
groups and DMF treated mice display a reduction of limb dyskinesia.
doi:10.1371/journal.pone.0016172.g003
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weeks, DMF treatment led to significantly reduced clasping scores
as compared to methocel treated controls (Fig. 3B,C). Addition-
ally, gait abnormalities were assessed by analyzing footprint
patterns of DMF or sham treated R6/2 mice walking along a
narrow tunnel. Analysis of gait width, stride length or overlap did
not reveal any significant differences between both groups, but also
failed to convincingly show differences over the course of disease
between sham-treated R6/2 mice and wild-type controls (data not
shown). In summary, DMF treatment resulted in a preservation of
motor functions in R6/2 mice.
DMF treatment preserves the morphology of neurons in
the striatum and the motor cortex
Since DMF treatment exerts beneficial effects on survival and
motor behaviour in R6/2 mice, we were interested in the
histopathological changes under DMF treatment. Numbers of
morphologically intact neurons were analyzed after cresyl violet
staining or immunohistochemistry for the NeuN antigen on day
80. Morphological criteria were applied to a blinded stereological
analysis of neurons in the striatum and motor cortex. In the
analysis of both NeuN positive or cresyl violet stained cells, DMF
treatment resulted in 1.5–2 fold higher numbers of intact neurons
both in the striatum as well as in the motor cortex (Tab. 1 and
Fig. 4A–H).
Since it is well known that there is no complete neuronal loss,
but still severe neurodegeneration in the striatum and the motor
cortex of R6/2 mice, the light microscopical data were
corroborated by semithin- and ultrasection analysis (Fig. 5). The
integrity of striatal and cortical neurons was relatively preserved in
DMF treated R6/2 mice (Fig. 5A,C,E,G,I,L) when compared with
the corresponding areas in the methocel treated controls
(Fig. 5B,D,F,H,K,M). In semithin sections of the striatum
(Fig. 5A,C) and of the motor cortex (Fig. 5G,I) of DMF treated
mice, most neurons appeared intact in the striatum and motor
cortex (Fig. 5A,C,G,I). In methocel treated mice, dark cells were
dispersed among intact neurons in the striatum and the motor
cortex (Fig. 5B,D,H,K). Electron microscopical analysis confirmed
the presence of degenerating neurons with darkened and shrunken
appearance in the striatum (Fig. 5F) and in the motor cortex
(Fig. 5M) when compared with intact light appearing neurons in
the respective areas of DMF treated mice (Fig. 5E,L). Nuclear
Figure 4. DMF leads to preservation of morphologically intact neurons. Representative images of the striatum (A,B and E,F) or motor cortex
(C,D and G,H) from DMF (A,C,E,G) or methocel treated mice (B,D,F,H) on day 80 are shown. Bar=100 mm. Arrows indicate intact, arrowheads indicate
degenerating neurons. (A–D) NeuN staining of the striatum (A,B) and the motor cortex (C,D) in R6/2 mice (day 80). Note the higher number of NeuN
immunoreactive neurons after DMF treatment (marked by arrows, arrowheads indicate degenerating striatal neurons with loss of NeuN
immunoreactivity). (E–H) Cresyl violet staining of the striatum (E,F) and motorcortex (G,H) in R6/2 mice. Note the higher number of intact neurons
after DMF treatment (marked by arrows) and the increased number of shrunken, dystrophic neurons after methocel treatment (marked by
arrowheads). False color images depicting cresyl violet staining in red are shown.
doi:10.1371/journal.pone.0016172.g004
Table 1. Quantification of neurons after Cresyl violet and NeuN staining.
Numbers of neurons Striatum p-value Motor cortex p-value n
DMF Methocel DMF Methocel
Cresyl violet [6SEM] 1075681 769.9635 0.0018 1384665 704.8681 ,0.0001 8/8
NeuN [6SEM] 637.8648 332630.2 ,0.0001 1092660 640.9661 ,0.0001 8/8
Blinded quantification of neurons after cresyl violet or NeuN staining revealed a significantly higher number of intact neurons in the striatum and in the motor cortex of
DMF treated mice.
doi:10.1371/journal.pone.0016172.t001
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neurons undergoing dark cell degeneration (Fig. 5M).
In summary, DMF treatment led to preservation of intact
neurons in the striatum and the motor cortex.
DMF treatment in R6/2 mice targets the Nrf2 pathway
After having established that DMF exerts beneficial effects on
neuronal integrity in R6/2 mice, we next analyzed the
mechanisms of DMF action. First, we investigated the effects of
DMF on the formation of Htt aggregates. To this end, we
performed immunohistochemistry for ubiquitin which reliably
detects Htt inclusions in R6/2 mice [15]. DMF treatment did not
affect the formation of Htt aggregates as measured by Htt or
ubiquitin immunoreactivity (Tab. 2). Similarly, staining for Mac-3
as a marker of activated phagocytes did not disclose a major
bystander immune reaction which could be modulated by DMF
treatment (data not shown).
DMF is a known inducer of phase 2 detoxifying enzymes and
both DMF and its primary metabolite monomethlyfumarate
(MMF) are thiol-reactive electrophiles [24,25,26]. This combina-
tion of properties suggests that the DMF may activate the Nrf2
transcriptional pathway known to mediate induction of phase 2
genes by SH-reactive electrophiles and play a major role in cell
and tissue defense against oxidative stress. Immunohistochemistry
for Nrf2 revealed a higher number of Nrf2 positive cells in the
striatum of DMF treated mice (Fig. 6A,B and Tab. 3). We next
Figure 5. DMF treatment prevents dark cell degeneration in R6/2 mice. (A,B) Overview images of semithin sections show the striatum of
DMF (A) and methocel treated (B) R6/2 mice at 80 days of age. Representative images are shown. (C,D) At higher enlargement (for localization see
rectangles), the light striatal neurons appear intact in the DMF treated mouse (C) whereas dark cells (arrows) are dispersed among intact neurons in
the methocel treated mouse (D). (E,F) Electron microscopy confirms neuronal integrity in DMF treated mice (E) and the condensed and shrunken
appearance of severely affected striatal neurons in methocel treated mice (F). (G,H) Semithin overviews display regular cortical morphology of the
DMF treated mouse (G), but an irregular appearance in the cortex of representative methocel treated mouse (H). (I,K) At higher enlargements
(rectangles) of corresponding layers the DMF treated mouse exhibits intact neurons (I) whereas the methocel treated mouse show multiple dark cells
of varying size (arrows) dispersed between single intact neurons (K). (L,M) Electron microscopy confirms the dark cell degeneration with shrunken
dark cytoplasm (arrows) and a ruffled nuclear envelope of a respective neuron (M) in contrast to the intact cortical neuron of a DMF treated mouse
(L). Both the intact and the dark neuron exhibit a prominent intranuclear round inclusion (x). Bars in A,B,G,H=100 mm; bars in C,D,I,K=20 mm; bars in
E,F,L,M=1 mm.
doi:10.1371/journal.pone.0016172.g005
Table 2. DMF does not influence aggregate formation in R6/2 mice.
Positive neurons Striatum p-value Motor cortex p-value n
DMF Methocel DMF Methocel
Huntingtin numbers 618.2654 613.2628 n.s. 541.065 494.7669 n.s. 8/8
Ubiquitin % [6SEM] 52.8864 47.5963 n.s. n.d. n.d. ----- 8/8
Blinded quantification of the absolute number of huntingtin positive profiles in the striatum or the motor cortex and the percentage of ubiquitin immunoreactive
neurons in the striatum did not reveal a significant difference between the DMF and methocel treated groups.
doi:10.1371/journal.pone.0016172.t002
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types of the striatum and motor cortex by double label
immunfluorescence and laser scanning confocal microscopy.
Double staining of Nrf2 with the neuronal marker NeuN revealed
an increased Nrf2 immunoreactivity after DMF treatment in
different neuronal subpopulations of the brain, especially in the
striatum and in the motor cortex (Fig. 6 C,D). After double
staining of Nrf2 with the astroglial marker GFAP, double labelled
cell were neither identified in DMF nor in methocel treated mice
(Fig. 6 E, F).
In summary, DMF treatment in R6/2 mice led to an increase in
Nrf2 staining in neuronal subpopulations which are relevant for
motor functions.
3.5 DMF exerts positive effects in the YAC128 model of
HD
Finally, the beneficial effects of DMF in the R6/2 mice were
corroborated in the YAC128 mouse as another well established
mouse model of HD. Analysing the forced motor behaviour on a
rotarod confirmed a trend towards preserved motor functions after
DMF treatment of YAC128 mice older than 22 weeks (Fig. 7A).
While there were no differences in body weight when analysing
mice up to a life span of one year (data not shown), DMF
treatment in YAC128 mice led to a reduction of limb dyskinesia as
measured by the clasping score (Fig. 7B). These beneficial effects
on the motor behavior were also seen in a histopathological
analysis on day 365. Blinded quantification of intact neurons in the
Figure 6. Increased Nrf2 immunoreactivity after DMF treatment. Representative images of the striatum from DMF (A, C, E) or methocel
treated mice (B, D, F) on day 80 are shown. (A,B) In contrast to methocel treated R6/2 mice, there is an increased number of Nrf2 positive cells after
DMF treatment (Nrf2 immunopositive cells are marked by arrows). Bar=100 mm. (C,D) Confocal laser scanning microscopy images after NeuN/Nrf2
double staining. In contrast to vehicle treated mice (D), a higher number of NeuN/Nrf2 double positive cells are observed in the striatum in DMF
treated R6/2 mice (C). Arrows mark NeuN/Nrf2 double labelled cells. Bar=20 mm. (E,F) Confocal laser scanning microscopy images after GFAP/Nrf2
double labelling. In the striatum, significant numbers of Nrf2 immunopositive astrocytes were neither identified after DMF treatment (E), nor in
control mice (F). Arrows indicate Nrf2 negative astrocytes. Bar=20 mm; images represent a Z-stack of 10 mm.
doi:10.1371/journal.pone.0016172.g006
Table 3. Quantification of Nrf2 positive cells in the striatum.
Positive neurons Striatum p-value n
DMF Methocel
Nrf2 [numbers 6 SEM] 579.1671 345.6625 0.0282 7/5
Blinded quantification of Nrf2 positive cells in the striatum revealed a
significantly higher number of Nrf2 positive cells in DMF treated mice.
doi:10.1371/journal.pone.0016172.t003
Fumaric Acid in Huntington’s Disease
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e16172striatum and motor cortex after cresyl violet staining revealed a
preservation of neuronal number after DMF treatment (Fig. 7C,D).
In summary, the beneficial effects of DMF in R6/2 mice were
also observed in YAC128 mice as another transgenic mouse model
of HD.
Discussion
We show that DMF treatment exerts beneficial effects on
survival time and motor functions in the R6/2 and YAC128
models of HD. The clinical efficacy of DMF in the R6/2 model
was corroborated by preservation of intact neurons and less
pronounced dark cell degeneration in the striatum and motor
cortex as well as an up-regulation of the transcription factor Nrf2
in striatal neurons.
As expected, R6/2 mice display a higher amount of free radicals
in the CNS indicating an increase in oxidative stress which may be
linked to neurodegeneration. Indeed, oxidative stress is known to
be a common underlying mechanism in the pathogenesis of many
neurodegenerative diseases causing damage to multiple cellular
components such as DNA, proteins and lipids [27,28]. Here,
fumaric acid esters which activate antioxidant response pathways
may provide neuroprotective effects [6]. Several studies revealed
that DMF is a potent inducer of phase 2 detoxifying enzymes [26]
and both DMF and its primary metabolite MMF are thiol-reactive
electrophiles [25]. These characteristics imply that fumarates may
activate the Nrf2 transcriptional pathway which is known to
mediate induction of phase 2 genes by SH-reactive electrophiles
and to play a major role in cell and tissue defense against oxidative
stress [29]. Indeed, several in vitro studies described protective
effects of DMF on neurons [30,31]. In cell culture, MMF
protected cultured neurons and astrocytes from oxidative stress
induced by H2O2 [6]. Other studies describing deprivation of
glutathione or toxicity of DMF and MMF in glial cultures used
much higher, non-physiological concentrations of both com-
pounds [32,33]. Very recent studies using Nrf2 deficient mice in a
chronic model of multiple sclerosis provide direct evidence for
DMF mediated neuroprotective effect via Nrf2 mediated regula-
Figure 7. DMF preserves motor functions in YAC128 mice. (A) Rotarod analysis. A cohort of YAC128 mice treated with DMF (n=23, black bars)
or methocel (n=22, white bars) is shown. Although DMF treatment leads to a trend towards longer times on the accelerating rod, there is no
significant difference between both groups. (B) Clasping Score. A cohort of YAC128 mice treated with DMF (n=23) or methocel (n=22) is shown. In
comparison to control mice (white bars), there is a trend towards reduced clasping behaviour in the DMF treated group (black bars) from the age of
47 weeks. (C) Blinded quantification of neuronal densities in the striatum after creysl violet staining on day 365 (n=3 per group). There is a significant
preservation of neuronal numbers after DMF treatment (black bar) as compared to methocel treatment (white bar, p=0.03). (D) Blinded
quantification of neuronal densities in the motor cortex after creysl violet staining on day 365 (n=3/5 per group). There is a significant preservation of
neuronal numbers after DMF treatment (black bar) as compared to methocel treatment (white bar, p=0.004).
doi:10.1371/journal.pone.0016172.g007
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the inhibitor of Nrf2, Keap-1, which leads to transfer of free Nrf2
into the nucleus and activation of anti-oxidative response elements.
A result of the activated Nrf2 pathway is cellular detoxification,
normalization of the energy metabolism and repair and/or
degradation of damaged proteins.
The Nrf2-mediated oxidative stress response was already
previously linked to protection of the CNS in a variety of
pathological conditions [34,35,36,37]. In particular, the impor-
tance of this pathway was recently implicated in the pathogenesis
of HD [38]. Furthermore, ex vivo studies and analyses of
neurodegenerative models for motor neuron disorders and
Parkinson’s disease disclosed that Nrf2 mediated neuroprotection
may not only be directly mediated, but in some models critically
involves effects via astrocytes [39,40,41,42].
In addition to its neuroprotective capacity, DMF may also
possess immunomodulatory effects which were at least proposed in
several dermatologic analyses in vitro [43,44,45,46,47]. In the R6/2
model, we did not observe a significant bystander immune
reactivity in the CNS which could be modulated by DMF. We
thus propose that DMF treatment in HD models primarily targets
neurons. This concept is in line with the observation that DMF
metabolites reach significant concentrations in the CNS [6]. To
further explore the neuroprotective potential of DMF, additional
studies in other models of HD and neurodegenerative diseases are
warranted.
The efficacy of DMF as an inducer of the oxidative stress
response in models of HD underlines the importance of free
radicals in the pathophysiology of HD. Indeed, mitochondrial
dysfunction, oxidative stress and energy depletion have long been
implicated in the pathogenesis of HD and stimulated several
therapeutic approaches. In particular, the treatment of R6/2
transgenic mice with dichloracetate which increases the activity of
the pyruvate dehydrogenase complex revealed positive effects.
Further studies employing antioxidants like a-lipoic acid [48]
observed beneficial effects and a significantly enhanced survival of
R6/2 mice. Similar results were achieved by administration of co-
enzyme Q10 [49]. While these effects may be based on the
improvement of mitochondrial function or the decrease of
oxidative damage, it seems conceivable that different disease
stages are governed by different prevailing pathomechanisms. This
concept could explain the decreasing efficacy of DMF at the later
disease stages in R6/2 mice.
In R6/2 mice, DMF leads to a preservation of intact neurons as
revealed by cresyl violet staining and immunohistochemistry for
the NeuN antigen. These light microscopy results were corrobo-
rated by semi- and ultrathin section analyses revealing a less
pronounced dark cell degeneration after DMF treatment. While
several reports point at a significant neuronal loss and striatal
atrophy in R6/2 mice [7,8,50] or YAC128 HD transgenic mice
[9,10], other studies only describe functional changes of neuronal
subpopulations in these models [51,52]. This concept was further
refined by the characterization of dark cell degeneration in striatal
and cortical neurons [8,53,54,55]. In our study, we therefore used
several histological approaches to describe a relative preservation
of morphologically intact neurons under DMF treatment as
compared to sham treated controls. Yet, the study design does not
allow conclusions on a putative overall loss of striatal or motor
cortex neuron numbers in R6/2 or YAC128 mice.
Many therapeutic approaches were tested in rodent models of
HD, including inhibition of histone deacetylation and methylation
[56,57], congo red [58,59], disaccharides [60], tiagabine [61],
transglutaminase inhibitors [62,63], caspase inhibitors [64] or also
tetracyclins [65,66,67]. Yet, many of these approaches were later
refuted in clinical trials or could not be reproduced in follow-up
studies as recently shown e.g. for minocyline or co-enzyme Q
[66,68]. This may in part be explained by the low number of
animals used, environmental factors or husbandry [69]. These
ambiguous results highlight the importance of a standardized
testing which was also implemented in the present study design
[69]. Using large cohorts as well as standardized therapy,
husbandry and testing batteries, we show that DMF exerts
beneficial effects in the two best characterized mouse models of
HD. While DMF does not influence the pathogensis of HD, it
exerts significant protective effects on the affected tissue. Given its
excellent side effect profile, further studies with DMF as a potential
neuroprotective approach in HD are warranted. Such trials may
also include combination therapy approaches to target different
pathomechanisms of HD which are possibly stage-specific.
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